Inhibition of PNCK inflames tumor microenvironment and sensitizes head and neck squamous cell carcinoma to immune checkpoint inhibitors
Inhibition of PNCK may be a potential strategy for treating HNSCC, as it may activate the immune response and improve the TME, thereby enhancing the efficacy of immunotherapy for HNSCC patients.
Authors
- Hongmei Ying
- Wenqian Xu
- Sufang Qiu (ORCID: https://orcid.org/0000-0001-7660-6955)
- Wanzun Lin (ORCID: https://orcid.org/0000-0003-3973-8849)
- Qin Ding
- Jianmin Wang (ORCID: https://orcid.org/0000-0001-6841-7943)
- Ying Li (ORCID: https://orcid.org/0000-0003-4012-6954)
- Tingting Lin (ORCID: https://orcid.org/0000-0002-6061-2311)
- Hanxuan Yang
- Xinqing Lin (ORCID: https://orcid.org/0000-0002-1582-7700)
- Youliang Weng
Institutions
- Fujian Medical University (CN)
- Shanghai Medical College of Fudan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- Fujian Provincial Cancer Hospital (CN)
- Shanghai Clinical Research Center (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1136/jitc-2024-009893
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- Wu Jieping Medical Foundation